Stockscreener 앱 받기
2.02
2.42%
-0.05
전일 마감가:
$2.07
열려 있는:
$2.06
하루 거래량:
49,125
Relative Volume:
0.08
시가총액:
$30.26M
수익:
$1.16M
순이익/손실:
$-12.02M
주가수익비율:
-1.9459
EPS:
-1.0381
순현금흐름:
$-10.16M
1주 성능:
-3.35%
1개월 성능:
+1.00%
6개월 성능:
+2.02%
1년 성능:
-15.48%
1일 변동 폭
$2.01
$2.07
1주일 범위
$1.99
$2.12
52주 변동 폭
$1.27
$9.19
Dare Bioscience Inc Stock (DARE) Company Profile
명칭
Dare Bioscience Inc
전화
858-926-7655
주소
3655 NOBEL DRIVE, SAN DIEGO, CA
Compare DARE vs VRTX, REGN, ARGX, ALNY, RVMD
| 주식 | 가격 | 시가총액 | 매출 | 순이익 | 현금흐름 | 주당 순 이익 |
|---|---|---|---|---|---|---|
DARE
Dare Bioscience Inc
|
2.02 | 30.26M | 1.16M | -12.02M | -10.16M | -1.0381 |
VRTX
Vertex Pharmaceuticals Inc
|
485.39 | 123.19B | 12.34B | 4.34B | 3.71B | 16.87 |
REGN
Regeneron Pharmaceuticals Inc
|
664.52 | 69.67B | 14.92B | 4.42B | 3.79B | 41.04 |
ARGX
Argen X Se Adr
|
877.62 | 54.58B | 4.16B | 1.29B | 734.26M | 19.58 |
ALNY
Alnylam Pharmaceuticals Inc
|
298.76 | 39.89B | 4.29B | 577.22M | 641.34M | 4.2086 |
RVMD
Revolution Medicines Inc
|
186.88 | 39.73B | 742.00K | -1.37B | -1.07B | -7.0731 |
Dare Bioscience Inc 주식(DARE)의 최신 뉴스
Daré Bioscience CEO, Sabrina Martucci Johnson, to Participate in Virtual Investor Closing Bell Event - The Manila Times
Price to sales forward of Dare Bioscience, Inc. – NASDAQ:DARE - TradingView
DARE Technical Analysis & Stock Price Forecast - Intellectia AI
Daré Bioscience launches prescription-free vaginal probiotic capsule for microbiome support - Contemporary OB/GYN
Dare Bioscience Company Profile & Introduction - Moomoo
Price to earnings forward of Dare Bioscience, Inc. – NASDAQ:DARE - TradingView
Dare Bioscience (DARE) director receives 23,696 RSUs in lieu of cash pay - Stock Titan
Dare Bioscience (DARE) director awarded 30,805 RSUs as board compensation - Stock Titan
Dare Bioscience (DARE) grants 38,862 RSUs to board director - Stock Titan
Dare Bioscience (DARE) director receives 26,540 RSUs in lieu of cash fees - Stock Titan
Director Jessica Grossman gets 26,066 RSUs at Dare Bioscience (NASDAQ: DARE) - Stock Titan
Daré Bioscience Announces Flora Sync LF5™ Is Now Available Through Its Direct-to-Consumer Platform - The Manila Times
Daré Bioscience Launches Flora Sync LF5 Vaginal Probiotic, Marks First Direct Consumer Product Revenue - Quiver Quantitative
Daré Bioscience’s vaginal probiotic is now for sale online - Stock Titan
Daré Bioscience, Inc.(NasdaqCM: DARE) added to Russell 3000E Growth Benchmark - marketscreener.com
Daré Bioscience, Inc.(NasdaqCM: DARE) added to Russell 3000E Index - marketscreener.com
Daré Bioscience, Inc.(NasdaqCM: DARE) added to Russell Microcap Index - marketscreener.com
Daré Bioscience, Inc.(NasdaqCM:DARE) added to Russell Microcap Growth Benchmark Index - marketscreener.com
Dare Bioscience Highlights Revenue Opportunity as CEO Discusses Upcoming Launch of Flora Sync LF5 in Virtual Investor What This Means Segment - marketscreener.com
Dare Bioscience Inc (DARE) Technical Analysis: Support, Resistance, Indicators & Moving Averages - TradingKey
Dare Bioscience, Inc. Actuals & Estimates (NASDAQ:DARE) - TradingView
DARE Forecast — Price Target — Prediction for 2027 - TradingView
Daré Bioscience Highlights Revenue Opportunity as CEO Discusses Upcoming Launch of Flora Sync LF5™ in Virtual Investor 'What This Means” Segment - The Manila Times
Daré Bioscience Highlights Revenue Opportunity as CEO - GlobeNewswire
Daré Bioscience Highlights Revenue Opportunity as CEO Discusses Upcoming Launch of Flora Sync LF5™ in Virtual Investor “What This Means” Segment - Yahoo! Finance Canada
Daré Bioscience, Inc. (DARE) Presents at BIO International Convention 2026Slideshow (NASDAQ:DARE) 2026-06-23 - Seeking Alpha
Daré Bioscience Issues New Corporate Investor Presentation - TipRanks
Form 8K Dare Bioscience Inc For: 22 June By Investing.com - Investing.com South Africa
Dare Bioscience (DARE) unveils June 22, 2026 corporate investor presentation - Stock Titan
Dare Bioscience Inc (DARE) Shareholder Structure: Major Shareholders & Institutional Holdings - TradingKey
Daré Bioscience to Present Corporate Strategy and Participate in Multiple Speaking Engagements at BIO International Convention 2026 - Quiver Quantitative
Daré Bioscience to Showcase Leadership in Women's Health Innovation at BIO International Convention 2026 - GlobeNewswire
Dare Bioscience Inc (DARE) Risk Assessment: Volatility, Financial Risk & Investment Risk - TradingKey
Dare Bioscience Inc (DARE) Financial Health: Profitability & Balance Sheet Analysis - TradingKey
Dare Bioscience Inc (DARE) Valuation: PE, PB & Fair Value Analysis - TradingKey
Dare Bioscience Inc (DARE) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution - TradingKey
Dare Bioscience Inc (DARE) Institutional Confidence - TradingKey
Dare Bioscience Inc (DARE) Earnings Forecast: Future EPS & Revenue Growth Estimates - TradingKey
Dare Bioscience Inc (DARE) Dividends & Stock Splits: Historical Payouts and Event Timeline - TradingKey
Ovaprene phase 3 interim data supports potential of monthly hormone-free contraceptive - Contemporary OB/GYN
Dare Bioscience (DARE) Holds Near Support After Marginal DeclineSector ETF Flow - newsline.com
Daré Bioscience Shareholders Back Governance and Capital Plans - The Globe and Mail
Daré Bioscience (NASDAQ: DARE) OKs equity line and boosts incentive plan shares - Stock Titan
Dare Bioscience (DARE) director receives 10,000 stock option grant - Stock Titan
Director Susan L. Kelley receives 10,000 Dare Bioscience (DARE) stock options - Stock Titan
Director at Dare Bioscience (NASDAQ: DARE) receives 10,000 stock options grant - Stock Titan
Director Gregory Matz receives 10,000 Dare Bioscience (DARE) stock options - Stock Titan
Dare Bioscience (DARE) director receives 10,000 stock options at $2.03 strike - Stock Titan
Dare Bioscience Inc Annual Shareholders Meeting Transcript - GuruFocus
Daré Bioscience to launch vaginal probiotic product - Investing.com
Daré Bioscience to launch vaginal probiotic product By Investing.com - Investing.com South Africa
Dare Bioscience Inc (DARE) 재무 분석
매출
순이익
현금흐름
주당 순 이익
2.64%
자본화:
|
볼륨(24시간):